Literature DB >> 11165086

Pluronic F-127 gels incorporating highly purified unsaturated fatty acids for buccal delivery of insulin.

M Morishita1, J M Barichello, K Takayama, Y Chiba, S Tokiwa, T Nagai.   

Abstract

The present study investigated the release profiles of insulin from Pluronic F-127 (PF-127) gel containing unsaturated fatty acids such as oleic acid (18:1), eicosapentaenoic acid (20:5) or docosahexaenoic acid (22:6) and the hypoglycemic effect of insulin following the buccal administration of the gel formulations in normal rats. Insulin release from the gels decreased in the presence of unsaturated fatty acids. Remarkable and continuous hypoglycemia was induced by all PF-127 gels (insulin dose, 25 IU/kg) containing unsaturated fatty acids. PF-127 gels containing oleic acid showed the highest pharmacological availability (15.9+/-7.9%). Our finding demonstrate that 20% PF-127 gels containing unsaturated fatty acids are potential formulations for the buccal delivery of insulin.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11165086     DOI： 10.1016/s0378-5173(00)00615-3

Source DB:  PubMed          Journal:  Int J Pharm        ISSN： 0378-5173            Impact factor:   5.875


  13 in total

Review 1.  A review of poloxamer 407 pharmaceutical and pharmacological characteristics.

Authors:  Gilles Dumortier; Jean Louis Grossiord; Florence Agnely; Jean Claude Chaumeil
Journal:  Pharm Res       Date:  2006-11-11       Impact factor: 4.200

2.  Enhancing thermal stability of a highly concentrated insulin formulation with Pluronic F-127 for long-term use in microfabricated implantable devices.

Authors:  Jason Li; Michael K Chu; Brian Lu; Sako Mirzaie; Kuan Chen; Claudia R Gordijo; Oliver Plettenburg; Adria Giacca; Xiao Yu Wu
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

Review 3.  Enhancing the buccal mucosal delivery of peptide and protein therapeutics.

Authors:  Thiago Caon; Liang Jin; Cláudia M O Simões; Raymond S Norton; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-08-29       Impact factor: 4.200

4.  Bioadhesive Drug Delivery System for Enhancing the Permeability of a BCS Class III Drug via Hot-Melt Extrusion Technology.

Authors:  Nicole S Mendonsa; Priyanka Thipsay; Dong Wuk Kim; Scott T Martin; Michael A Repka
Journal:  AAPS PharmSciTech       Date:  2017-02-28       Impact factor: 3.246

5.  Eudragit S100 entrapped insulin microspheres for oral delivery.

Authors:  Deepti Jain; Amulya K Panda; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2005-09-20       Impact factor: 3.246

6.  In vitro and in vivo evaluation of topical formulations of spantide II.

Authors:  Loice Kikwai; R Jayachandra Babu; Renata Prado; Alexandra Kolot; Cheryl A Armstrong; John C Ansel; Mandip Singh
Journal:  AAPS PharmSciTech       Date:  2005-10-31       Impact factor: 3.246

7.  Semi-interpenetrating network (sIPN) co-electrospun gelatin/insulin fiber formulation for transbuccal insulin delivery.

Authors:  Leyuan Xu; Natasha Sheybani; Shunlin Ren; Gary L Bowlin; W Andrew Yeudall; Hu Yang
Journal:  Pharm Res       Date:  2014-07-17       Impact factor: 4.200

8.  Effect of HPMC and mannitol on drug release and bioadhesion behavior of buccal discs of buspirone hydrochloride: In-vitro and in-vivo pharmacokinetic studies.

Authors:  A Jaipal; M M Pandey; S Y Charde; P P Raut; K V Prasanth; R G Prasad
Journal:  Saudi Pharm J       Date:  2014-12-08       Impact factor: 4.330

Review 9.  Achievements in Thermosensitive Gelling Systems for Rectal Administration.

Authors:  Maria Bialik; Marzena Kuras; Marcin Sobczak; Ewa Oledzka
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

10.  Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy.

Authors:  Marzia Cirri; Lavinia Maestrini; Francesca Maestrelli; Natascia Mennini; Paola Mura; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.